224 related articles for article (PubMed ID: 2833902)
1. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Weiner ES; Earnshaw WC; Senécal JL; Bordwell B; Johnson P; Rothfield NF
Arthritis Rheum; 1988 Mar; 31(3):378-85. PubMed ID: 2833902
[TBL] [Abstract][Full Text] [Related]
2. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.
Weiner ES; Hildebrandt S; Senécal JL; Daniels L; Noell S; Joyal F; Roussin A; Earnshaw W; Rothfield NF
Arthritis Rheum; 1991 Jan; 34(1):68-77. PubMed ID: 1845841
[TBL] [Abstract][Full Text] [Related]
4. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
[TBL] [Abstract][Full Text] [Related]
5. Anticentromere and anticentriole antibodies in the scleroderma spectrum.
Tuffanelli DL; McKeon F; Kleinsmith DM; Burnham TK; Kirschner M
Arch Dermatol; 1983 Jul; 119(7):560-6. PubMed ID: 6859899
[TBL] [Abstract][Full Text] [Related]
6. A long-term longitudinal study of anticentromere antibodies.
Tramposch HD; Smith CD; Senecal JL; Rothfield N
Arthritis Rheum; 1984 Feb; 27(2):121-4. PubMed ID: 6607733
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies in systemic sclerosis.
Vázquez-Abad D; Rothfield NF
Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
[TBL] [Abstract][Full Text] [Related]
9. Clinical correlation of anticentromere antibodies.
Zuber M; Gotzen R; Filler I
Clin Rheumatol; 1994 Sep; 13(3):427-32. PubMed ID: 7835004
[TBL] [Abstract][Full Text] [Related]
10. Anticentromere antibodies--clinical correlates.
Wade JP; Sack B; Schur PH
J Rheumatol; 1988 Dec; 15(12):1759-63. PubMed ID: 3265957
[TBL] [Abstract][Full Text] [Related]
11. Proteins responsible for anticentromere activity found in the sera of patients with CREST-associated Raynaud's phenomenon.
Kremer L; Alvaro-Gracia JM; Ossorio C; Avila J
Clin Exp Immunol; 1988 Jun; 72(3):465-9. PubMed ID: 3048807
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
Uchida K; Kondo H; Kashiwazaki S
Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
[No Abstract] [Full Text] [Related]
13. Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases.
Hossny E; Hady HA; Mabrouk R
Pediatr Allergy Immunol; 2000 Nov; 11(4):250-5. PubMed ID: 11110581
[TBL] [Abstract][Full Text] [Related]
14. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.
Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski T; Jabłońska S; Maul GG
Arch Dermatol Res; 1990; 282(2):76-83. PubMed ID: 2162156
[TBL] [Abstract][Full Text] [Related]
15. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
16. Immunological characterization of heterochromatin protein p25beta autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma.
Furuta K; Hildebrandt B; Matsuoka S; Kiyosawa K; Reimer G; Luderschmidt C; Chan EK; Tan EM
J Mol Med (Berl); 1998 Jan; 76(1):54-60. PubMed ID: 9462868
[TBL] [Abstract][Full Text] [Related]
17. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
Johanet C; Agostini MM; Vayssairat M; Abuaf N
Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody to centromere (kinetochore) in scleroderma sera.
Moroi Y; Peebles C; Fritzler MJ; Steigerwald J; Tan EM
Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1627-31. PubMed ID: 6966403
[TBL] [Abstract][Full Text] [Related]
19. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
[TBL] [Abstract][Full Text] [Related]
20. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease.
Goldman JA
Ann Rheum Dis; 1989 Sep; 48(9):771-5. PubMed ID: 2802800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
